ALMS: the cashflow

MyFinsight

For the quarter ending 2025-09-30, ALMS had -$86,873K decrease in cash & cash equivalents over the period. -$110,909K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-110,752	-39,642
Stock-based compensation	9,787	25,630
Net accretion of discounts on marketable securities	-1,724	-2,152
Depreciation and amortization	916	1,713
Non-cash lease expense	537	624
Gain on bargain purchase in connection with the acelyrin merger	0	187,907
Impairment of long-lived assets	529	-
Research and development prepaid expenses	-2,053	-7,373
Other prepaid expenses and other assets	-13,250	-96
Other assets, non-current	3,350	1,723
Accounts payable	-10,424	-1,162
Deferred revenue	-667	2,611
Research and development accrued expenses	-6,102	11,037
Other accrued expenses and current liabilities	-3,983	6,537
Operating lease liabilities	-979	-1,349
Other liabilities, non-current	0	168
Deferred income tax liability	0	8,561
Net cash used in operating activities	-110,909	-186,707
Maturities of marketable securities	161,149	144,274
Purchases of marketable securities	137,113	24,535
Purchases of property and equipment	0	653
Cash, cash equivalents and restricted cash acquired in connection with the acelyrin merger	0	49,742
Net cash provided by (used in) investing activities	24,036	168,828
Repurchase of common stock shares issued upon early exercised restricted common stock	0	17
Proceeds from issuance of common stock under the 2024 espp	0	766
Net cash provided by financing activities	0	749
Net (decrease) increase in cash, cash equivalents and restricted cash	-86,873	-17,130
Cash and cash equivalents at beginning of period	170,632	-
Cash and cash equivalents at end of period	66,629	-

Unit: Thousand (K) dollars